Merrimack Pharmaceuticals (MACK)
(Delayed Data from NSDQ)
$14.73 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.71 -0.02 (-0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Merrimack Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 2 | 2 | 2 | 3 | 22 |
Income After Depreciation & Amortization | -2 | -2 | -2 | -3 | -22 |
Non-Operating Income | 1 | 0 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 2 |
Pretax Income | -1 | -2 | -2 | -3 | -23 |
Income Taxes | 0 | 0 | 0 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -1 | -2 | -2 | -3 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 4 |
Net Income (GAAP) | -1 | -2 | -2 | -3 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -2 | -2 | -2 | -3 | -20 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 2 |
Income After Depreciation & Amortization | -2 | -2 | -2 | -3 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 14.30 | 13.52 | 13.41 | 13.38 | 13.35 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 |
Diluted Net EPS (GAAP) | -0.08 | -0.11 | -0.18 | -0.23 | -1.30 |
Fiscal Year end for Merrimack Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.49 | 0.53 | 0.57 | 0.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.49 | -0.53 | -0.57 | -0.45 |
Non-Operating Income | NA | 0.26 | 0.25 | 0.18 | 0.18 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -0.23 | -0.28 | -0.39 | -0.27 |
Income Taxes | NA | 0.01 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.24 | -0.28 | -0.39 | -0.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.24 | -0.28 | -0.39 | -0.27 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 14.34 | 14.32 | 14.29 | 14.25 |
Diluted EPS Before Non-Recurring Items | NA | -0.01 | -0.02 | -0.03 | -0.02 |
Diluted Net EPS (GAAP) | NA | -0.01 | -0.02 | -0.03 | -0.02 |